Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 27 entries
Sorted by: Best Match Show Resources per page
[Noninvasive characterization of a case of Danon disease].

Revista espanola de cardiologia

Braksator W, Chybowska B, Kuch M, Dluzniewski M.
PMID: 20334819
Rev Esp Cardiol. 2010 Apr;63(4):493-5.

No abstract available.

Cite
Braksator W, Chybowska B, Kuch M, et al. Caracterización no invasiva de un caso de enfermedad de Danon. [Noninvasive characterization of a case of Danon disease]. Rev Esp Cardiol. 2010;63(4):493-5
Braksator, W., Chybowska, B., Kuch, M., & Dluzniewski, M. (2010). Caracterización no invasiva de un caso de enfermedad de Danon. [Noninvasive characterization of a case of Danon disease]. Revista espanola de cardiologia, 63(4), 493-5.
Braksator, Wojciech, et al. "Caracterización no invasiva de un caso de enfermedad de Danon." [Noninvasive characterization of a case of Danon disease]. Revista espanola de cardiologia vol. 63,4 (2010): 493-5.
Braksator W, Chybowska B, Kuch M, Dluzniewski M. Caracterización no invasiva de un caso de enfermedad de Danon. [Noninvasive characterization of a case of Danon disease]. Rev Esp Cardiol. 2010 Apr;63(4):493-5. Spanish. PMID: 20334819.
Copy Download .nbib Format: NLM
Cinacalcet and gastrointestinal bleeding risk in patients receiving hemodialysis.

Pharmacoepidemiology and drug safety

Liu J, Guo H, Lin TC, Wetmore JB, Bradbury BD, Gilbertson DT, Nieman K, Peng Y, Sprafka JM, Dluzniewski PJ.
PMID: 34363294
Pharmacoepidemiol Drug Saf. 2022 Feb;31(2):141-148. doi: 10.1002/pds.5337. Epub 2021 Aug 19.

PURPOSE: Secondary hyperparathyroidism (SHPT) is common among dialysis patients, and calcimimetics are a mainstay of treatment. This study assessed whether cinacalcet use is associated with gastrointestinal bleeding in a large hemodialysis cohort.METHODS: A linked database of clinical records and...

Cite
Liu J, Guo H, Lin TC, et al. Cinacalcet and gastrointestinal bleeding risk in patients receiving hemodialysis. Pharmacoepidemiol Drug Saf. 2021;31(2):141-148doi: 10.1002/pds.5337.
Liu, J., Guo, H., Lin, T. C., Wetmore, J. B., Bradbury, B. D., Gilbertson, D. T., Nieman, K., Peng, Y., Sprafka, J. M., & Dluzniewski, P. J. (2022). Cinacalcet and gastrointestinal bleeding risk in patients receiving hemodialysis. Pharmacoepidemiology and drug safety, 31(2), 141-148. https://doi.org/10.1002/pds.5337
Liu, Jiannong, et al. "Cinacalcet and gastrointestinal bleeding risk in patients receiving hemodialysis." Pharmacoepidemiology and drug safety vol. 31,2 (2022): 141-148. doi: https://doi.org/10.1002/pds.5337
Liu J, Guo H, Lin TC, Wetmore JB, Bradbury BD, Gilbertson DT, Nieman K, Peng Y, Sprafka JM, Dluzniewski PJ. Cinacalcet and gastrointestinal bleeding risk in patients receiving hemodialysis. Pharmacoepidemiol Drug Saf. 2022 Feb;31(2):141-148. doi: 10.1002/pds.5337. Epub 2021 Aug 19. PMID: 34363294.
Copy Download .nbib Format: NLM
PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress.

Cancer immunology research

Klopotowska M, Bajor M, Graczyk-Jarzynka A, Kraft A, Pilch Z, Zhylko A, Firczuk M, Baranowska I, Lazniewski M, Plewczynski D, Goral A, Soroczynska K, Domagała J, Marhelava K, Slusarczyk A, Retecki K, Ramji K, Krawczyk M, Temples MN, Sharma B, Lachota M, Netskar H, Malmberg KJ, Zagozdzon R, Winiarska M.
PMID: 34853030
Cancer Immunol Res. 2021 Dec 01; doi: 10.1158/2326-6066.CIR-20-1023. Epub 2021 Dec 01.

Oxidative stress, caused by the imbalance between reactive species generation and the dysfunctional capacity of antioxidant defenses, is one of the characteristic features of cancer. Here, we quantified hydrogen peroxide in the tumor microenvironment and demonstrated that hydrogen peroxide...

Cite
Klopotowska M, Bajor M, Graczyk-Jarzynka A, et al. PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress. Cancer Immunol Res. 2021;doi: 10.1158/2326-6066.CIR-20-1023.
Klopotowska, M., Bajor, M., Graczyk-Jarzynka, A., Kraft, A., Pilch, Z., Zhylko, A., Firczuk, M., Baranowska, I., Lazniewski, M., Plewczynski, D., Goral, A., Soroczynska, K., Domagała, J., Marhelava, K., Slusarczyk, A., Retecki, K., Ramji, K., Krawczyk, M., Temples, M. N., Sharma, B., Lachota, M., Netskar, H., Malmberg, K. J., Zagozdzon, R., & Winiarska, M. (2021). PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress. Cancer immunology research, . https://doi.org/10.1158/2326-6066.CIR-20-1023
Klopotowska, Marta, et al. "PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress." Cancer immunology research vol. (2021). doi: https://doi.org/10.1158/2326-6066.CIR-20-1023
Klopotowska M, Bajor M, Graczyk-Jarzynka A, Kraft A, Pilch Z, Zhylko A, Firczuk M, Baranowska I, Lazniewski M, Plewczynski D, Goral A, Soroczynska K, Domagała J, Marhelava K, Slusarczyk A, Retecki K, Ramji K, Krawczyk M, Temples MN, Sharma B, Lachota M, Netskar H, Malmberg KJ, Zagozdzon R, Winiarska M. PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress. Cancer Immunol Res. 2021 Dec 01; doi: 10.1158/2326-6066.CIR-20-1023. Epub 2021 Dec 01. PMID: 34853030.
Copy Download .nbib Format: NLM
PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress.

Cancer immunology research

Klopotowska M, Bajor M, Graczyk-Jarzynka A, Kraft A, Pilch Z, Zhylko A, Firczuk M, Baranowska I, Lazniewski M, Plewczynski D, Goral A, Soroczynska K, Domagala J, Marhelava K, Slusarczyk A, Retecki K, Ramji K, Krawczyk M, Temples MN, Sharma B, Lachota M, Netskar H, Malmberg KJ, Zagozdzon R, Winiarska M.
PMID: 34853030
Cancer Immunol Res. 2021 Dec 01; doi: 10.1158/2326-6066.CIR-20-1023. Epub 2021 Dec 01.

Oxidative stress, caused by the imbalance between reactive species generation and the dysfunctional capacity of antioxidant defenses, is one of the characteristic features of cancer. Here, we quantified hydrogen peroxide in the tumor microenvironment (TME) and demonstrated that hydrogen...

Cite
Klopotowska M, Bajor M, Graczyk-Jarzynka A, et al. PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress. Cancer Immunol Res. 2021;doi: 10.1158/2326-6066.CIR-20-1023.
Klopotowska, M., Bajor, M., Graczyk-Jarzynka, A., Kraft, A., Pilch, Z., Zhylko, A., Firczuk, M., Baranowska, I., Lazniewski, M., Plewczynski, D., Goral, A., Soroczynska, K., Domagala, J., Marhelava, K., Slusarczyk, A., Retecki, K., Ramji, K., Krawczyk, M., Temples, M. N., Sharma, B., Lachota, M., Netskar, H., Malmberg, K. J., Zagozdzon, R., & Winiarska, M. (2021). PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress. Cancer immunology research, . https://doi.org/10.1158/2326-6066.CIR-20-1023
Klopotowska, Marta, et al. "PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress." Cancer immunology research vol. (2021). doi: https://doi.org/10.1158/2326-6066.CIR-20-1023
Klopotowska M, Bajor M, Graczyk-Jarzynka A, Kraft A, Pilch Z, Zhylko A, Firczuk M, Baranowska I, Lazniewski M, Plewczynski D, Goral A, Soroczynska K, Domagala J, Marhelava K, Slusarczyk A, Retecki K, Ramji K, Krawczyk M, Temples MN, Sharma B, Lachota M, Netskar H, Malmberg KJ, Zagozdzon R, Winiarska M. PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress. Cancer Immunol Res. 2021 Dec 01; doi: 10.1158/2326-6066.CIR-20-1023. Epub 2021 Dec 01. PMID: 34853030.
Copy Download .nbib Format: NLM
Migration of liver sinusoidal leukocytes to the liver colon adenocarcinoma metastases.

Comparative hepatology

Durowicz S, Lukomska B, Dluzniewska J, Laszuk D, Olszewski WL.
PMID: 14960205
Comp Hepatol. 2004 Jan 14;3:S53. doi: 10.1186/1476-5926-2-S1-S53.

No abstract available.

Cite
Durowicz S, Lukomska B, Dluzniewska J, et al. Migration of liver sinusoidal leukocytes to the liver colon adenocarcinoma metastases. Comp Hepatol. 2004;3:S53doi: 10.1186/1476-5926-2-S1-S53.
Durowicz, S., Lukomska, B., Dluzniewska, J., Laszuk, D., & Olszewski, W. L. (2004). Migration of liver sinusoidal leukocytes to the liver colon adenocarcinoma metastases. Comparative hepatology, 3S53. https://doi.org/10.1186/1476-5926-2-S1-S53
Durowicz, Sergiusz, et al. "Migration of liver sinusoidal leukocytes to the liver colon adenocarcinoma metastases." Comparative hepatology vol. 3 (2004): S53. doi: https://doi.org/10.1186/1476-5926-2-S1-S53
Durowicz S, Lukomska B, Dluzniewska J, Laszuk D, Olszewski WL. Migration of liver sinusoidal leukocytes to the liver colon adenocarcinoma metastases. Comp Hepatol. 2004 Jan 14;3:S53. doi: 10.1186/1476-5926-2-S1-S53. PMID: 14960205; PMCID: PMC2409446.
Copy Download .nbib Format: NLM
Lipid Testing Trends in the US Before and After the Release of the 2013 Cholesterol Treatment Guidelines.

Clinical epidemiology

Levintow SN, Reading SR, Saul BC, Yu Y, Reams D, McGrath LJ, Philip K, Dluzniewski PJ, Brookhart MA.
PMID: 32801921
Clin Epidemiol. 2020 Aug 04;12:835-845. doi: 10.2147/CLEP.S259757. eCollection 2020.

BACKGROUND: The 2013 ACC/AHA cholesterol treatment guidelines removed the recommendation to treat adults at risk of cardiovascular disease to goal levels of low-density lipoprotein cholesterol (LDL-C). We anticipated that the frequency of LDL-C testing in clinical practice would decline...

Cite
Levintow SN, Reading SR, Saul BC, et al. Lipid Testing Trends in the US Before and After the Release of the 2013 Cholesterol Treatment Guidelines. Clin Epidemiol. 2020;12:835-845doi: 10.2147/CLEP.S259757.
Levintow, S. N., Reading, S. R., Saul, B. C., Yu, Y., Reams, D., McGrath, L. J., Philip, K., Dluzniewski, P. J., & Brookhart, M. A. (2020). Lipid Testing Trends in the US Before and After the Release of the 2013 Cholesterol Treatment Guidelines. Clinical epidemiology, 12835-845. https://doi.org/10.2147/CLEP.S259757
Levintow, Sara N, et al. "Lipid Testing Trends in the US Before and After the Release of the 2013 Cholesterol Treatment Guidelines." Clinical epidemiology vol. 12 (2020): 835-845. doi: https://doi.org/10.2147/CLEP.S259757
Levintow SN, Reading SR, Saul BC, Yu Y, Reams D, McGrath LJ, Philip K, Dluzniewski PJ, Brookhart MA. Lipid Testing Trends in the US Before and After the Release of the 2013 Cholesterol Treatment Guidelines. Clin Epidemiol. 2020 Aug 04;12:835-845. doi: 10.2147/CLEP.S259757. eCollection 2020. PMID: 32801921; PMCID: PMC7414934.
Copy Download .nbib Format: NLM
Epoxy matrix with triaromatic mesogenic unit in dielectric spectroscopy observation.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

Włodarska M, Mossety-Leszczak B, Bąk GW, Kisiel M, Dłużniewski M, Okrasa L.
PMID: 29328951
Spectrochim Acta A Mol Biomol Spectrosc. 2018 Apr 05;194:102-110. doi: 10.1016/j.saa.2018.01.001. Epub 2018 Jan 04.

No abstract available.

Cite
Włodarska M, Mossety-Leszczak B, Bąk GW, et al. Epoxy matrix with triaromatic mesogenic unit in dielectric spectroscopy observation. Spectrochim Acta A Mol Biomol Spectrosc. 2018;194:102-110doi: 10.1016/j.saa.2018.01.001.
Włodarska, M., Mossety-Leszczak, B., Bąk, G. W., Kisiel, M., Dłużniewski, M., & Okrasa, L. (2018). Epoxy matrix with triaromatic mesogenic unit in dielectric spectroscopy observation. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 194102-110. https://doi.org/10.1016/j.saa.2018.01.001
Włodarska, Magdalena, et al. "Epoxy matrix with triaromatic mesogenic unit in dielectric spectroscopy observation." Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy vol. 194 (2018): 102-110. doi: https://doi.org/10.1016/j.saa.2018.01.001
Włodarska M, Mossety-Leszczak B, Bąk GW, Kisiel M, Dłużniewski M, Okrasa L. Epoxy matrix with triaromatic mesogenic unit in dielectric spectroscopy observation. Spectrochim Acta A Mol Biomol Spectrosc. 2018 Apr 05;194:102-110. doi: 10.1016/j.saa.2018.01.001. Epub 2018 Jan 04. PMID: 29328951.
Copy Download .nbib Format: NLM
Potent but transient immunosuppression of T-cells is a general feature of CD71.

Communications biology

Grzywa TM, Sosnowska A, Rydzynska Z, Lazniewski M, Plewczynski D, Klicka K, Malecka-Gieldowska M, Rodziewicz-Lurzynska A, Ciepiela O, Justyniarska M, Pomper P, Grzybowski MM, Blaszczyk R, Wegrzynowicz M, Tomaszewska A, Basak G, Golab J, Nowis D.
PMID: 34893694
Commun Biol. 2021 Dec 10;4(1):1384. doi: 10.1038/s42003-021-02914-4.

CD71

Cite
Grzywa TM, Sosnowska A, Rydzynska Z, et al. Potent but transient immunosuppression of T-cells is a general feature of CD71. Commun Biol. 2021;4(1):1384doi: 10.1038/s42003-021-02914-4.
Grzywa, T. M., Sosnowska, A., Rydzynska, Z., Lazniewski, M., Plewczynski, D., Klicka, K., Malecka-Gieldowska, M., Rodziewicz-Lurzynska, A., Ciepiela, O., Justyniarska, M., Pomper, P., Grzybowski, M. M., Blaszczyk, R., Wegrzynowicz, M., Tomaszewska, A., Basak, G., Golab, J., & Nowis, D. (2021). Potent but transient immunosuppression of T-cells is a general feature of CD71. Communications biology, 4(1), 1384. https://doi.org/10.1038/s42003-021-02914-4
Grzywa, Tomasz M, et al. "Potent but transient immunosuppression of T-cells is a general feature of CD71." Communications biology vol. 4,1 (2021): 1384. doi: https://doi.org/10.1038/s42003-021-02914-4
Grzywa TM, Sosnowska A, Rydzynska Z, Lazniewski M, Plewczynski D, Klicka K, Malecka-Gieldowska M, Rodziewicz-Lurzynska A, Ciepiela O, Justyniarska M, Pomper P, Grzybowski MM, Blaszczyk R, Wegrzynowicz M, Tomaszewska A, Basak G, Golab J, Nowis D. Potent but transient immunosuppression of T-cells is a general feature of CD71. Commun Biol. 2021 Dec 10;4(1):1384. doi: 10.1038/s42003-021-02914-4. PMID: 34893694.
Copy Download .nbib Format: NLM
Potent but transient immunosuppression of T-cells is a general feature of CD71.

Communications biology

Grzywa TM, Sosnowska A, Rydzynska Z, Lazniewski M, Plewczynski D, Klicka K, Malecka-Gieldowska M, Rodziewicz-Lurzynska A, Ciepiela O, Justyniarska M, Pomper P, Grzybowski MM, Blaszczyk R, Wegrzynowicz M, Tomaszewska A, Basak G, Golab J, Nowis D.
PMID: 34893694
Commun Biol. 2021 Dec 10;4(1):1384. doi: 10.1038/s42003-021-02914-4.

CD71

Cite
Grzywa TM, Sosnowska A, Rydzynska Z, et al. Potent but transient immunosuppression of T-cells is a general feature of CD71. Commun Biol. 2021;4(1):1384doi: 10.1038/s42003-021-02914-4.
Grzywa, T. M., Sosnowska, A., Rydzynska, Z., Lazniewski, M., Plewczynski, D., Klicka, K., Malecka-Gieldowska, M., Rodziewicz-Lurzynska, A., Ciepiela, O., Justyniarska, M., Pomper, P., Grzybowski, M. M., Blaszczyk, R., Wegrzynowicz, M., Tomaszewska, A., Basak, G., Golab, J., & Nowis, D. (2021). Potent but transient immunosuppression of T-cells is a general feature of CD71. Communications biology, 4(1), 1384. https://doi.org/10.1038/s42003-021-02914-4
Grzywa, Tomasz M, et al. "Potent but transient immunosuppression of T-cells is a general feature of CD71." Communications biology vol. 4,1 (2021): 1384. doi: https://doi.org/10.1038/s42003-021-02914-4
Grzywa TM, Sosnowska A, Rydzynska Z, Lazniewski M, Plewczynski D, Klicka K, Malecka-Gieldowska M, Rodziewicz-Lurzynska A, Ciepiela O, Justyniarska M, Pomper P, Grzybowski MM, Blaszczyk R, Wegrzynowicz M, Tomaszewska A, Basak G, Golab J, Nowis D. Potent but transient immunosuppression of T-cells is a general feature of CD71. Commun Biol. 2021 Dec 10;4(1):1384. doi: 10.1038/s42003-021-02914-4. PMID: 34893694.
Copy Download .nbib Format: NLM
Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies.

Pharmacoepidemiology and drug safety

Levintow SN, Orroth KK, Breskin A, Park AS, Flores Arredondo JH, Dluzniewski P, Navar AM, Sørensen HT, Brookhart MA.
PMID: 34894377
Pharmacoepidemiol Drug Saf. 2021 Dec 11; doi: 10.1002/pds.5396. Epub 2021 Dec 11.

PURPOSE: Clinical trials have demonstrated efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in reducing risk of cardiovascular disease events, but effectiveness in routine clinical care has not been well-studied. We used negative control outcomes to assess potential...

Cite
Levintow SN, Orroth KK, Breskin A, et al. Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies. Pharmacoepidemiol Drug Saf. 2021;doi: 10.1002/pds.5396.
Levintow, S. N., Orroth, K. K., Breskin, A., Park, A. S., Flores Arredondo, J. H., Dluzniewski, P., Navar, A. M., Sørensen, H. T., & Brookhart, M. A. (2021). Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies. Pharmacoepidemiology and drug safety, . https://doi.org/10.1002/pds.5396
Levintow, Sara N, et al. "Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies." Pharmacoepidemiology and drug safety vol. (2021). doi: https://doi.org/10.1002/pds.5396
Levintow SN, Orroth KK, Breskin A, Park AS, Flores Arredondo JH, Dluzniewski P, Navar AM, Sørensen HT, Brookhart MA. Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies. Pharmacoepidemiol Drug Saf. 2021 Dec 11; doi: 10.1002/pds.5396. Epub 2021 Dec 11. PMID: 34894377.
Copy Download .nbib Format: NLM
Potent but transient immunosuppression of T-cells is a general feature of CD71.

Communications biology

Grzywa TM, Sosnowska A, Rydzynska Z, Lazniewski M, Plewczynski D, Klicka K, Malecka-Gieldowska M, Rodziewicz-Lurzynska A, Ciepiela O, Justyniarska M, Pomper P, Grzybowski MM, Blaszczyk R, Wegrzynowicz M, Tomaszewska A, Basak G, Golab J, Nowis D.
PMID: 34893694
Commun Biol. 2021 Dec 10;4(1):1384. doi: 10.1038/s42003-021-02914-4.

CD71

Cite
Grzywa TM, Sosnowska A, Rydzynska Z, et al. Potent but transient immunosuppression of T-cells is a general feature of CD71. Commun Biol. 2021;4(1):1384doi: 10.1038/s42003-021-02914-4.
Grzywa, T. M., Sosnowska, A., Rydzynska, Z., Lazniewski, M., Plewczynski, D., Klicka, K., Malecka-Gieldowska, M., Rodziewicz-Lurzynska, A., Ciepiela, O., Justyniarska, M., Pomper, P., Grzybowski, M. M., Blaszczyk, R., Wegrzynowicz, M., Tomaszewska, A., Basak, G., Golab, J., & Nowis, D. (2021). Potent but transient immunosuppression of T-cells is a general feature of CD71. Communications biology, 4(1), 1384. https://doi.org/10.1038/s42003-021-02914-4
Grzywa, Tomasz M, et al. "Potent but transient immunosuppression of T-cells is a general feature of CD71." Communications biology vol. 4,1 (2021): 1384. doi: https://doi.org/10.1038/s42003-021-02914-4
Grzywa TM, Sosnowska A, Rydzynska Z, Lazniewski M, Plewczynski D, Klicka K, Malecka-Gieldowska M, Rodziewicz-Lurzynska A, Ciepiela O, Justyniarska M, Pomper P, Grzybowski MM, Blaszczyk R, Wegrzynowicz M, Tomaszewska A, Basak G, Golab J, Nowis D. Potent but transient immunosuppression of T-cells is a general feature of CD71. Commun Biol. 2021 Dec 10;4(1):1384. doi: 10.1038/s42003-021-02914-4. PMID: 34893694; PMCID: PMC8664950.
Copy Download .nbib Format: NLM
Disseminated Juvenile Xanthogranuloma and Hemophagocytic Lymphohistiocytosis Developed During Treatment of Acute Lymphoblastic Leukemia: Case Report.

Frontiers in oncology

Pawińska-Wa Sikowska K, Cwiklinska M, Wyrobek E, Balwierz W, Bukowska-Strakova K, Dluzniewska A, Gozdzik J, Drabik G, Rygielska M, Stepien K, Skoczen S.
PMID: 32719740
Front Oncol. 2020 Jul 03;10:921. doi: 10.3389/fonc.2020.00921. eCollection 2020.

The association between acute lymphoblastic leukemia (ALL), non-Langerhans cell histiocytosis (non-LCH), and hemophagocytic lymphohistiocytosis (HLH), to the best of our knowledge, has not been published to date. Juvenile xanthogranuloma (JXG), as a type of non-LCH, is usually a benign...

Cite
Pawińska-Wa Sikowska K, Cwiklinska M, Wyrobek E, et al. Disseminated Juvenile Xanthogranuloma and Hemophagocytic Lymphohistiocytosis Developed During Treatment of Acute Lymphoblastic Leukemia: Case Report. Front Oncol. 2020;10:921doi: 10.3389/fonc.2020.00921.
Pawińska-Wa Sikowska, K., Cwiklinska, M., Wyrobek, E., Balwierz, W., Bukowska-Strakova, K., Dluzniewska, A., Gozdzik, J., Drabik, G., Rygielska, M., Stepien, K., & Skoczen, S. (2020). Disseminated Juvenile Xanthogranuloma and Hemophagocytic Lymphohistiocytosis Developed During Treatment of Acute Lymphoblastic Leukemia: Case Report. Frontiers in oncology, 10921. https://doi.org/10.3389/fonc.2020.00921
Pawińska-Wa Sikowska, Katarzyna, et al. "Disseminated Juvenile Xanthogranuloma and Hemophagocytic Lymphohistiocytosis Developed During Treatment of Acute Lymphoblastic Leukemia: Case Report." Frontiers in oncology vol. 10 (2020): 921. doi: https://doi.org/10.3389/fonc.2020.00921
Pawińska-Wa Sikowska K, Cwiklinska M, Wyrobek E, Balwierz W, Bukowska-Strakova K, Dluzniewska A, Gozdzik J, Drabik G, Rygielska M, Stepien K, Skoczen S. Disseminated Juvenile Xanthogranuloma and Hemophagocytic Lymphohistiocytosis Developed During Treatment of Acute Lymphoblastic Leukemia: Case Report. Front Oncol. 2020 Jul 03;10:921. doi: 10.3389/fonc.2020.00921. eCollection 2020. PMID: 32719740; PMCID: PMC7350519.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 27 entries